Abstract
Anti-CD20 monoclonal antibody Rituximab(RTX) has been widely used in the treatment of refractory or relapsed lupus nephritis(LN), but the optimal regimen and dosage of RTX have not been defined. In this study, we investigate the clinical efficacy and safety of ultra-low dose Rituximab regimen for the treatment of LN.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
